Optibiotix Plc transition to a commercial business agreeing deals with Tata, Sacco and Nutrilinea

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, provides the following technical, regulatory and commercial update on its SlimBiome(R) product platform.

Technical Update

OptiBiotix has developed an improved version of SlimBiome(R) using advanced processing technology which provides the following benefits:-

i. Creating a single homogenous product reducing component separation in transport and improving product consistency. This opens up new application opportunities in areas which lack the ability to blend or remix SlimBiome(R) (e.g. in store bakeries)

ii. Enhanced solubility giving better product presentation and greatly enhancing flavour and mouthfeel. This improves the taste and consumer experience of products containing SlimBiome(R) such as ‘GoFigure(R)’ shakes and bars

iii. Improved dispersion in water opening up new applications areas to meets demand for ‘on the go’ products

   iv.   Lower manufacturing costs due to less waste and more efficient production processes

Commercial and Regulatory Update

OptiBiotix has made significant progress developing and enhancing its pipeline of innovative products with a strong scientific and clinical evidence base. This has attracted commercial interest from a range of manufacturing, retail and corporate partners. Recent commercial developments include:-

i. The Company has obtained FDA registration for both its LP-LDL(R) and SlimBiome(R) product ranges allowing access to the US market

ii. The Company will be launching its improved version of SlimBiome(R) at Supply Side West and exhibiting with a potential joint development partner, Cereal Ingredients Inc from Kansas, USA. Cereal Ingredients is a privately held specialty ingredients manufacturer, dedicated to the development and manufacture of unique, high-quality products that contribute a meaningful point of difference. Cereal Ingredients are looking to incorporate SlimBiome(R) into their range of cereal based particulates and ingredients, aimed at the nutraceutical, health and wellbeing sectors of the industry.

Further product development is ongoing with a number of manufacturers, corporates and large retailers to extend SlimBiome(R)’s application into ‘Health & Wellbeing’ food and beverage products. This is to coincide with increased consumer awareness of using functional natural ingredients as part of a healthy lifestyle to manage and reduce the risks of illness and disease.

Stephen O’Hara, CEO of OptiBiotix, commented: “We have made significant progress in our transition from a research and development company to a commercial business, recently agreeing deals with Tata, Sacco and Nutrilinea; companies with high industry reputations and a global network of distribution partners. This announcement updates investors on the technical and commercial progress of our SlimBiome(R) product platform, building on its proven science and consumer efficacy in GoFigure(R) products. As we build the range of applications, products and geographic scope of SlimBiome(R) with new manufacturing and distribution partners, the scale of the opportunity enlarges allowing us to fully exploit the revenue generating potential of our products. If successful, this low risk, low cost approach to accessing multiple consumer healthcare and pharmaceutical markets around the world with multiple products has the potential to cumulatively generate substantive revenues in the forthcoming years across all platforms.”

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Facebook
    Twitter
    LinkedIn
    Optibiotix Health Plc

    More articles like this

    Optibiotix Health Plc

    NutraIngredients Awards shortlist announced

    NutraIngredients is pleased to announce the shortlisted finalists for the 2018 edition of the NutraIngredients Awards … with the winners announced at our exclusive awards evening in Geneva on 16th May. The shortlisted finalistsfor the 10

    Optibiotix Health Plc

    OptiBiotix Health plc Launch of Slimbiome® in Nutri-bites®

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, and high cholesterol, today announced the launch of its award winning SlimBiome® in Nutri-Bites® with its US partner, Cereal Ingredients (“CII”), at the 2018 Natural

    Optibiotix Health Plc

    OptiBiotix Health PLC OptiBiotix Capital Reorganisation

    OptiBiotix Health plc (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes announced on 28 November 2017 that it intended to seek a cancellation of its share premium account (the “Capital Reduction”) in

    Optibiotix Health Plc

    Optibiotix Health PLC In a Strong Position

    Optibiotix Health PLC (LON:OPTI) Chief Executive Officer Stephen O’Hara talks to tells Proactive Investors about focussing on the commercialisation of their technology across the company’s platforms.

    Optibiotix Health Plc

    Functional weight loss ingredient, SlimBiome brought to US

    OptiBiotix Health PLC (LON:OPTI), a specialist in the development of functional ingredients to modulate the human microbiome, has entered into a manufacturing and supply agreement with Cereal Ingredients. The agreement grants Cereal Ingredients a licence to

    Optibiotix Health Plc

    SlimBiome® – Supporting hunger-free weight management

    Slimbiome® is OptiBiotix’s patented combination of natural ingredients, identified and developed by leading experts in nutrition and metabolism, which supports scientifically substantiated weight loss claims. In independent tests the component ingredients have shown reductions in calorie intake

    Optibiotix Health Plc

    OptiBiotix Health PLC Proposed Directorate Changes

    OptiBiotix Health PLC (LON:OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, today announced that subject to the completion of normal regulatory due diligence Neil Davidson CBE will be appointed as Non- Executive Chairman on 1 January 2018. Adam Reynolds, the current Non-Executive Chairman will

    Optibiotix Health Plc

    Optibiotix Health PLC on Kelloggs’ Sugar Levels Cut

    Following the announcement today from Kelloggs to cut the amount of sugar in its three top selling children’s cereals, we caught up with Stephen O’Hara, CEO of OptiBiotix Health PLC (LON:OPTI) for his thoughts:   “We are really